Results 191 to 200 of about 210,905 (300)

An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge. [PDF]

NPJ Vaccines
de Jong R, Zhou F, Andersen TK, Stockhofe-Zurwieden N, Cox RJ, Bogen B, Grodeland G.   +6 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Viscosity of concentrated mRNA solutions: Implications for downstream processing

Biotechnology Progress, EarlyView.
Abstract Messenger RNA (mRNA) therapeutics can be used to protect against infectious disease and for the treatment of cancers and genetic disorders. In order to obtain the desired therapeutic dosage, it is necessary to concentrate the mRNA to levels where the viscosity of the mRNA solutions can become significant.
Amin Javidanbardan, Fatemeh Najafi, Ziqiao Wang, Andrew L. Zydney   +3 more
wiley   +1 more source

Direct Cytoplasmic Transcription and Trimeric RBD Design Synergize to Enhance DNA Vaccine Potency Against SARS-CoV-2. [PDF]

Pharmaceutics
Nam Y, Shin SC, Cho SW, Ahn HJ.
europepmc   +1 more source

Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden

ChemFoodChem, EarlyView.
ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley   +1 more source

Correction: Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant. [PDF]

Virol J
Zhou Y, Zhang T, Wang Z, Xu X.
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Evaluation of genotype matched recombinant DNA vaccine for protection against genotype VII velogenic Newcastle disease virus in Pakistan. [PDF]

Sci Rep
Razzaq S, Riaz A, Siddique N, Saif-Ur-Rehman, Shah MA, Naeem K, Saleem G.   +6 more
europepmc   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations. [PDF]

Mol Ther Adv
Aleman S, Ahlén G, Yan J, Ljungman P, Bergman P, Nordentoft CAB, Appelberg S, Alisjahbana A, Cadossi M, Salati S, Tobin K, Tuvesson O, Tegel H, Gidlund EK, Weber F, Larsson O, Höglund U, Buggert M, Hober S, Frelin L, Mirazimi A, Sällberg M.   +21 more
europepmc   +1 more source